Molecular Epidemiology of Antimalarial Drug Resistance

Molecular epidemiology of antimalarial drug resistance integrates genomic, transcriptomic and population‐level analyses to track the emergence and spread of parasite variants that undermine therapeutic efficacy. Central to this field is the identification of mutations in genes such as pfK13, pfcrt and pfmdr1 that confer reduced susceptibility to artemisinin and its partner drugs. High‐throughput genotyping and sequencing approaches enable researchers to distinguish recrudescent infections from new infections, to monitor minority clones and to quantify multiplicity of infection. Such insights inform treatment guidelines, guide policy on combination therapies and underpin surveillance networks across endemic regions. By combining molecular markers with clinical efficacy data and geospatial mapping, this discipline offers real‐time intelligence on resistance hotspots, supports targeted interventions and underlines the global imperative of preserving antimalarial drug portfolios.

Research from Nature Portfolio

Recent studies have revealed intricate post‐treatment parasite dynamics that persist despite extended artemisinin‐based regimens. Longitudinal amplicon sequencing in paediatric cohorts demonstrated that multiclonal ring‐stage parasites often survive submicroscopic clearance thresholds, emphasising the need for optimised dosing strategies in high-transmission settings. In parallel, comparative analyses of traditional markers (msp1, msp2, glurp) and novel microsatellites have refined PCR correction methods in therapeutic efficacy trials. By evaluating match-counting versus Bayesian algorithms, researchers have highlighted discrepancies in recrudescence classification, pointing to standardised genotyping panels that improve accuracy in differentiating treatment failure from reinfection.

Molecular Epidemiology of Antimalarial Drug Resistance publication trend

The graph below shows the total number of articles in molecular epidemiology of antimalarial drug resistance across all publications each year (not limited to Nature Index journals).

Technical terms

Amplicon sequencing: Targeted deep sequencing of PCR-amplified genomic regions to detect low-frequency variants in parasite populations.

Multiplicity of infection (MOI): The number of genetically distinct parasite clones co-infecting a single host, reflecting transmission intensity.

Recrudescence: The return of blood-stage parasites from a persistent infection following incomplete clearance by therapy.

Microsatellites: Short tandem repeat DNA loci used as highly polymorphic markers for distinguishing parasite strains.

pfK13: A gene encoding a kelch propeller protein in Plasmodium falciparum; specific mutations are associated with artemisinin resistance.

References

1. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nature Communications (2024).
2. A Biotinylated cpFIT-PNA Platform for the Facile Detection of Drug Resistance to Artemisinin in Plasmodium falciparum. ACS Sensors (2024).
3. A genomic platform for surveillance and antigen discovery in Plasmodium spp. using long-read amplicon sequencing. Cell Reports Methods (2023).
4. Microsatellites reveal high polymorphism and high potential for use in anti-malarial efficacy studies in areas with different transmission intensities in mainland Tanzania. Malaria Journal (2024).
5. Assessment of different genotyping markers and algorithms for distinguishing Plasmodium falciparum recrudescence from reinfection in Uganda. Scientific Reports (2025).